Analysed CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ) News Sources
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
14-04-2026
yahoo.com
Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701
22-04-2026
yahoo.com
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
12-05-2026
yahoo.com
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
21-05-2026
yahoo.com
Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study
01-06-2026
marketbeat.com
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
28-07-2026
yahoo.com
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
04-08-2026
yahoo.com
What is the current price of CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ)?
The current price of CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ) is $11.13.
CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ) absolute price change since previous trading day?
The absolute price change of CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ) since the previous trading day is $0.44.
CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ) percentage price change since previous trading day?
The percentage price change of CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ) since the previous trading day is 4.116%.
What is the most recent average sentiment score for CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ)?
The most recent average sentiment score for CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ) is 75 out of 100.
What is the most recent average sentiment for CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ)?
The most recent sentiment for CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ) is .
SEC-8K** Filing Available For CORBUS PHARMACEUTICALS HOLDI (CRBP:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.